Hey mate, from the half yearly:
"Notably, despite the decline in revenue the earnings generated from this segment grew materially under this streamlined model as efficiencies in the business were increasingly realised and the product portfolio was rationalised to maximise returns. This trend in margin expansion is expected to continue into the second half of the 2017 financial year. "
I haven't got too bullish however given extra sales and marketing expected to be incurred.
- Forums
- ASX - By Stock
- PBP
- Looks quiet
Looks quiet, page-22
Featured News
Add PBP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online